Robust H1 results give Optos rosy outlook
This article was originally published in Clinica
Retinal scanning specialist Optos has announced positive results for the first half of fiscal 2007 and stated its intent to become a major player in the primary eye care market. The Dunfermline, Scotland-based company recorded 29% growth in revenue at $40.2m during that period and a 299% increase in operating profit after share-based payments to $2.9m.
You may also be interested in...
As arguments rage over whether the UK regulator has rushed its assessment of the Pfizer/BioNTech vaccine, the European Medicines Agency explains why its conditional marketing authorization approach is taking a little longer.
The IVDR implementation schedule is problematic. European notified bodies say solutions must be grasped if public health is not to suffer.
Amid several new and updated draft guidance documents and the potential approach of the first approval, interchangeability continues to be a buzzword in US biosimilars. AbbVie has projected that two Humira (adalimumab) biosimilars will hold the designation when they launch in 2023.